Cutler Group’s Cardiff Oncology CRDF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-2,500
Closed -$5K 4893
2020
Q3
$5K Buy
+2,500
New +$16.5K ﹤0.01% 3466
2017
Q1
Sell
-160
Closed -$33K 6476
2016
Q4
$33K Sell
160
-253
-61% -$59.1K ﹤0.01% 2950
2016
Q3
$28K Buy
413
+259
+168% +$94.4K ﹤0.01% 3070
2016
Q2
$28K Sell
154
-13
-8% -$4.48K ﹤0.01% 2996
2016
Q1
$6K Sell
167
-15
-8% -$5.1K ﹤0.01% 4622
2015
Q4
$7K Buy
+182
New +$71.3K ﹤0.01% 4519

Other funds holding CRDF

Cutler Group's CRDF Position: Q4 2021 in Review

Cutler Group sold out of Cardiff Oncology (CRDF) in Q4 2021, closing a stake of 600 shares — an estimated $3K sold.

Cutler Group first reported a position in CRDF in Q1 2016 and held it in 8 quarters. The position peaked at $15K in Q3 2016. 87 funds tracked by Wall St. Rank hold CRDF as of Q4 2021.

  • Cutler Group reported no remaining Cardiff Oncology position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 600 Cardiff Oncology shares in Q4 2021, an estimated $3K.
  • Cutler Group first reported a position in Cardiff Oncology in Q1 2016 and held it in 8 quarters.
  • Cutler Group's Cardiff Oncology position peaked at $15K in Q3 2016.
  • 87 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.